Arovella Therapeutics (ALA) Q4 2025 TU earnings summary

Executive summary

• Advanced IND application preparation for ALA-101, targeting first-in-human Phase 1 trial in early 2026.

• Secured exclusive option from Baylor College of Medicine for two novel CARs targeting solid tumours, including neuroblastoma and hepatocellular carcinoma.

• Expanded management and research teams, including new Senior Director of Clinical Development and research scientist appointments.

• Established new research laboratory at Jumar Bioincubator to accelerate solid tumour program development.

• Announced retirement of Non-Executive Chairman, with interim Chair appointed.

Financial highlights

• Cash and cash equivalents at 30 June 2025 totaled $20.9 million.

• Net cash outflow from operating activities for the quarter was $2.8 million.

• Research and development and staff costs accounted for 89% of operating outflows.

• Payments to related parties for the quarter were $160,465, covering director fees and salaries.

• Estimated 7.5 quarters of funding available based on current cash burn.

Outlook and guidance

• Phase 1 clinical trial for ALA-101 expected to commence in early 2026, with funding secured through patient enrolment and initial data reporting.

• Continued progress anticipated for solid tumour programs, including CLDN18.2 and IL-12-TM integration.

• Ongoing evaluation of new technologies for acquisition to enhance the CAR-iNKT platform.